Compare Amgen, Inc. (AMGN) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Gigacloud Technology Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Gigacloud Technology Inc trades at $34.35 (market cap $1.25B). The key difference: Amgen, Inc. is far larger — about 156.9× Gigacloud Technology Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| AMGN | GCT | |
|---|---|---|
Market Cap | $196.12B | $1.25B |
Sector | Health | Technology |
52-Week High | $388.16 | $51.80 |
52-Week Low | $271.18 | $20.26 |
Enterprise Value | $241.41B | $1.36B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GigaCloud Technology (GCT) trades at $34.41, down 1.21% today, with a bullish technical signal and strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate, and maintains robust profitability with a 10.77% net income margin. Revenue growth is projected to rise from $1.29B in 2025 to $1.4B in 2026, supported by positive analyst sentiment and inclusion in TIME's World's Growth Leaders 2026 list.
The outlook for GCT is positive, driven by earnings momentum and strategic expansions into Europe and AI-edge technology. Key risks include market volatility, competitive pressures in the furniture sector, and potential fiduciary concerns highlighted in recent news. With 66.7% of analysts rating it a Buy and a $56 price target from Seeking Alpha suggesting 76% upside, the stock presents growth potential but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
